TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $31.83 Average PT from Brokerages

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have been assigned an average recommendation of “Moderate Buy” from the six brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $31.83.

A number of equities analysts have commented on the company. B. Riley increased their target price on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. HC Wainwright reissued a “buy” rating and set a $49.00 target price on shares of TG Therapeutics in a report on Tuesday, August 6th. Finally, The Goldman Sachs Group upped their price target on TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th.

TG Therapeutics Price Performance

Shares of TG Therapeutics stock opened at $23.73 on Wednesday. The business has a 50 day simple moving average of $21.63 and a two-hundred day simple moving average of $18.06. TG Therapeutics has a 12 month low of $6.46 and a 12 month high of $25.70. The stock has a market capitalization of $3.67 billion, a P/E ratio of 103.17 and a beta of 2.21. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The business had revenue of $73.47 million during the quarter, compared to analysts’ expectations of $65.92 million. During the same quarter in the prior year, the firm earned ($0.34) earnings per share. The business’s revenue was up 357.0% compared to the same quarter last year. As a group, analysts predict that TG Therapeutics will post 0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On TG Therapeutics

Large investors have recently made changes to their positions in the stock. Pingora Partners LLC purchased a new stake in shares of TG Therapeutics in the fourth quarter valued at approximately $27,000. Ashton Thomas Private Wealth LLC purchased a new position in TG Therapeutics in the second quarter worth approximately $35,000. DekaBank Deutsche Girozentrale purchased a new position in TG Therapeutics in the first quarter worth approximately $58,000. nVerses Capital LLC grew its position in TG Therapeutics by 34.9% in the second quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $103,000 after acquiring an additional 1,500 shares during the period. Finally, Quarry LP grew its position in TG Therapeutics by 9.1% in the second quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 503 shares during the period. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.